A number of neurodegenerative diseases including Parkinson's disease, dementia with Lewy bodies (DLB) and multiple system atrophy are characterized by the formation and intraneuronal accumulation of fibrillar aggregates of a-synuclein (a-syn) protein in affected brain regions. These and other findings suggest that the accumulation of a-syn in the brain plays an important role in the pathogenesis of these diseases. However, more recently it has been reported that early amyloid aggregates or 'soluble oligomers' are the pathogenic species that lead to neurodegeneration and neuronal cell death rather than the later 'mature fibrils'. In this study, we investigated the presence of a-syn oligomers in brain lysates prepared from frozen post-mortem brains of normal, Alzheimer's disease and DLB patients. The brain extracts were subjected to high speed centrifugation, to remove insoluble a-syn aggregates, followed by specific detection of soluble oligomers in the supernatants by employing FILA-1, an antibody that specifically binds to a-syn aggregates, but not to a-syn monomers, or to tau or b-amyloid aggregates. Using this novel enzyme-linked immunosorbent assay (ELISA) method to quantify the amounts of a-syn oligomers in the brain extracts, our data clearly show an increase in the levels of soluble oligomers of a-syn in the DLB brains compared to those with Alzheimer's disease and the controls (P50.0001). Our findings provide strong evidence to support the contention that elevated soluble oligomers of a-syn are involved in the pathogenesis of DLB. Furthermore, these findings establish FILA-1 as a very sensitive tool for the detection of oligomeric forms of a-syn in human brain lysates.
Introduction
The discovery of mutations (Polymeropoulos et al., 1997; Kruger et al., 1998; Zarranz et al., 2004) in the gene encoding -synuclein (-syn) protein, in familial cases of Parkinson's disease, supports the idea that -syn plays a critical role in the pathogenesis of Parkinson's disease Irvine, 2000, 2002; Martin et al., 2004; Paleologou et al., 2005; Amer et al., 2006) . Furthermore, genetic studies have recently revealed that a triplication of the SNCA gene (encoding -syn) is associated with severe forms of early-onset familial Parkinson's disease and some features of dementia with Lewy bodies (DLB) (Singleton et al., 2003) . Moreover, duplications of SNCA cause familial Parkinson's disease closely resembling idiopathic late-onset Parkinson's disease (Chartier-Harlin et al., 2004; Ibanez et al., 2004) . These studies indicate that increased expression of wild-type -syn enhances the risk of developing Parkinson's disease and that the protein level of -syn might be an important determinant of the severity of the Parkinsonian phenotype. Neuropathological studies in sporadic Parkinson's disease have revealed the presence of cytoplasmic inclusions that are abundant in degenerating dopaminergic neurons of the substantia nigra, and in other cortical and subcortical neurons. These inclusions are known as Lewy bodies (LBs) and Lewy neurites; both are formed from deposits of -syn protein (Spillantini et al., 1997) . Intracellular inclusions formed from -syn are also a prominent feature of DLB and multiple system atrophy, which, together with Parkinson's disease, are collectively designated synucleinopathies (Spillantini et al., 1998) . Recently, it has been reported that lesions similar to those found in the human synucleinopathies can be created in transgenic animals expressing high levels of human wild-type or mutant -syn (Maslaih et al., 2000; Kahle et al., 2001; Giasson et al., 2002; Lo Bianco et al., 2002) . These studies also provide strong evidence for the central role of -syn deposition in the pathogenesis of synucleinopathies. Protein conformation-dependent neurotoxicity is a common theme in other neurodegenerative disorders such as Alzheimer's disease, the 'tauopathies', Huntington's disease and the prion diseases Cookson, 2005) . Recent studies support the idea that early amyloid aggregates called 'soluble oligomers' are the pathogenic components that drive neurodegeneration and neuronal cell death, rather than mature amyloid fibrils (Conway et al., 2000; , 2003a Bucciantini et al., 2002; Kayed et al., 2003; Paleologou et al., 2005; Tabner et al., 2005a, b; Walsh et al., 2005; Amer et al., 2006) .
Recently, it has been shown that there are elevated amounts of soluble lipid-associated -syn oligomers in the brain homogenates of Parkinson's disease and DLB compared with normal brains (Sharon et al., 2003) . In the present article, we have investigated the presence of soluble -syn oligomers in DLB, Alzheimer's disease and normal control brain homogenates. Accordingly, a novel enzyme-linked immunosorbent assay (ELISA) has been developed to specifically detect -syn oligomers. Total -syn was also measured using ELISA in an attempt to measure the overall level of expression of this protein in post-mortem brain samples of control, Alzheimer's disease and DLB patients in comparison with the presence of the oligomeric -syn in the same samples.
Methods

Materials
Fish skin gelatin (45%) was purchased from Sigma-Aldrich Corporation (St Louis, MO, USA). The SureBlue TM Elite TMB ELISA substrate was obtained from KPL (Maryland, USA). The goat anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody was acquired from DakoCytomation (Glostrup, Denmark). Recombinant human fulllength -syn was expressed in Escherichia coli and purified as described previously (Jensen et al., 1997; El-Agnaf et al., 1998a, b) , followed by an additional reverse phase-high pressure liquid chromatography purification step on a Jupiter C8 column (Phenomenex, Torrance, CA, USA) in 0.1% trifluoroacetic acid with an acetonitrile gradient. Recombinant tau40 was expressed and purified as described previously (Goedert and Jakes, 1990) , and the synthetic b-amyloid protein (Ab) was synthesized and purified as described recently . Affinity purified rabbit antibody toward human -syn (ASY1) has been described previously (Jensen et al., 2000) . Rabbit FILA-1 IgG, specific for fibrillar and soluble oligomeric forms of -syn, was prepared as described by Lindersson et al. (2004) .
Patients
Twenty-four patients with DLB (17 males, 7 females), 15 patients with Alzheimer's disease (5 males, 10 females) and seven control subjects (four males and three females) were drawn from the Manchester Brain Bank (Table 1) . Patients with DLB fulfilled International Consensus (clinical and pathological) criteria for DLB (McKeith et al., 1996) . Diagnosis of Alzheimer's disease was consistent with clinical (McKhann et al., 1984) and neuropathological (Mirra et al., 1991) criteria, and all patients were assessed pathologically as being at Braak stage 5 or 6 (Braak and Braak, 1991) . Control subjects died without known neurological or psychiatric illness, though most showed minimal amounts of Alzheimer's disease-type pathology (Table 1) and often significant cerebrovascular disease at postmortem. All brains had been collected at autopsy with Local Ethical Committee approval.
Brain lysate preparation
Frozen post-mortem brain samples (3 g) of frontal cerebral cortex from neuropathologically assessed control, Alzheimer's disease and DLB patients were obtained with ethical consent from the Manchester Brain Bank. Samples were homogenized in 3 ml of CelLytic buffer, consisting of mild detergent, bicine and 150 mM NaCl (SigmaAldrich Company Ltd), containing a cocktail of protease inhibitors, including AEBSF, aprotinin, E-64, EDTA and leupeptin (CalbiochemNovabiochem Corporation, San Diego, USA) and centrifuged at 3000 g for 30 min. The supernatant was collected and the total protein concentration was measured and all samples were adjusted to 3 mg/ml and then stored at -80 C. The samples were thawed at room temperature directly before analysis.
Dot blotting
Soluble oligomers and insoluble fibrils were produced from recombinant human -syn and isolated by gel filtration (Lashuel et al., 2002) and sucrose gradient centrifugation (Lindersson et al., 2005) . To analyse their stability, oligomers and fibrils were treated with increasing concentrations of urea (6.5, 7 and 8 M) or sodium dodecyl sulphate (SDS) (0.25, 0.5, 1 and 2%) for 6 h at room temperature. Sixty nanograms of protein was directly spotted onto the nitrocellulose membrane which was allowed to dry at room temperature before proceeding with the detection process. The membrane was blocked in 5% dried skimmed milk for 1 h. After washing, the membrane was probed with FILA-1 at a concentration of 2 ng/ml. Following an additional wash with TBST, the membrane was incubated with HRPconjugated swine-anti-rabbit secondary antibody (DAKO, Copenhagen, Denmark) for 1 h at room temperature. Proteins were visualized using ECL reagents (Pierce, USA) as described by the manufacturer.
To demonstrate the specificity of rabbit FILA-1 antibody towards -syn fibrils, we pre-absorbed FILA-1 antibody with fibrils assembled from -syn, Ab(1-42), and tau40. -Syn fibrils were assembled from recombinant -syn protein (5 mg/ml) in PBS and isolated by sucrose gradient centrifugation (Lindersson et al., 2005) . Ab fibrils were assembled from synthetic Ab(1-42) peptide in 1 mg/ml as described for -syn fibrils. Tau40 fibrils were prepared by incubating 2 mg/ml 0.37 0.14 tau40 in PBS at 37 C for 5 days in the presence of 0.4 mg/ml heparin, 2 mM EDTA, 2 mM PEFA and 0.02% sodium azide. The fibril formation in the samples was confirmed by the Thioflavin-T binding assay and/or electron microscopy. The insoluble aggregates were isolated by centrifugation before using them for pre-absorption of FILA-1 antibody. FILA-1 antibody (20 mg/ml) was pre-absorped with excesssyn, Ab or tau fibrils for 4 h at RT. The insoluble material was isolated by centrifugation and the resulting supernatant was diluted 1:2 in 5% skimmed milk. -Syn fibrils were sonicated and spotted onto a nitrocellulose membrane in two-fold dilutions. The membrane was blocked in 5% skimmed milk for 1 h and probed with pre-absorbed FILA-1 overnight at 4 C. Proteins were visualized as described above. Finally, the membrane was reprobed with anti--synuclein antibody ASY1 (Jensen et al., 2000) to verify equal amounts of -syn fibrils on the dot blot.
Measuring total a-syn in human brain homogenates -Syn in brain lysates was measured using a sandwich ELISA assay. An anti-human -syn monoclonal antibody 211 (Santa Cruz Biotechnology, USA), which recognizes amino acids 121-125 of human -syn, was used for capture and anti-human -syn polyclonal antibody FL-140 (Santa Cruz Biotechnology), raised against recombinant fulllength human -syn, was used for antigen detection through a HRP-linked spectrometric assay. ELISA plate (Nunc Maxisorb, NUNC, Denmark) was coated for overnight incubation at 4 C, with 1 mg/ml of 211 (100 ml/well), in 200 mM NaHCO 3 (Sigma-Aldrich), pH 9.6, containing 0.02% (w/v) sodium azide, then washed four times with PBST (PBS containing 0.05% Tween 20) and incubated with 200 ml/ well of blocking buffer (PBS containing 2.5% gelatin and 0.05% Tween 20) for 2 h at 37 C. The plate was washed with PBST, and 100 ml of the brain lysate samples (3 mg/ml) were added to each well and incubated at 37 C for 3 h. After washing with PBST, 100 ml of FL-140 antibody (0.2 mg/ml) diluted to 1:1000 in blocking buffer was added, and then incubated for another 2 h at 37 C. The wells were washed with PBST and incubated with 100 ml/well of HRP-labelled anti-rabbit antibody (DAKO, Denmark) diluted 1:10 000 in the blocking buffer and incubated for 1 h at 37 C. Bound HRP activities were assayed by colour development using the SureBlue TM Elite TMB microwell peroxidase system (KPL, USA). The reaction was stopped with 0.3 M sulfuric acid (100 ml/well), and absorbance values at 450 nm were determined. The standard curve for the ELISA assay was carried out using 100 ml/well of recombinant human -syn solution at different concentrations (0.002, 0.005, 0.01, 0.025, 0.05, 0.1, 0.3, 0.6, 1.0, 1.5 and 2.0 mg/ml) of the protein in PBS. Also, different concentrations of recombinant human b-syn and -syn were included as negative controls for the assay. The relative concentration estimates of thesyn protein in the brain lysates were calculated according to each standard curve and the dilution factor. The intra-and inter-assay precision was 59%.
A novel ELISA using FILA-1 IgG
Brain homogenates from control, Alzheimer's disease and DLB were diluted 1:1 in 400 mM NaHCO 3 , pH 9.6, containing sodium azide. Hundred microlitre per well of the samples was added in 96-well plate (Nunc Maxisorb, NUNC, Denmark) and incubated at 37 C for 2 h. This was followed by a triple wash with PBST (PBS containing 0.05% Tween 20) prior to incubation with blocking buffer (2.5% gelatin in PBST) at 37 C for 2 h. The microtiter plate was then washed three times with PBST followed by addition of 100 ml/well of FILA-1 (1 mg/ml). The plate was incubated at 37 C for 2 h and then washed three times as described above and the secondary antibody [Goat anti-rabbit HRP (1:10 000)] was added and the plate was incubated at 37 C for 1 h. Following a final wash, 100 ml of TMB was added and the colour was left to develop at room temperature for 30 min. The reaction was stopped with 0.3 N H 2 SO 4 , and the absorbance values were measured at 450 nm.
Pre-adsorption of FILA-1 IgG with aggregated a-syn FILA-1 was mixed with five different dilutions (10, 1, 0.1, 0.01, 0.001 mg/ml in PBS) of aggregated -syn. The formation of -syn fibrils was confirmed by the Thioflavin-T binding assay and electron microscopy. PBS and fresh -syn (10 mg/ml) were also used as controls instead of aggregated -syn. Pre-adsorption was carried out by rotating the mixtures overnight at room temperature. This was followed by ultracentrifugation at 100 000 g for 30 min and the supernatants were collected. The latter was used as the preadsorbed FILA-1 to detect aggregated -syn by the ELISA as described above.
Immunohistochemical staining
Brains had been fixed in 10% buffered formalin for a period of between 1 and 3 months. Blocks of tissue were cut from the temporal cortex (Brodmann areas 21/22) and hippocampus (at the level of the geniculate bodies) and processed routinely into paraffin wax. Sections were cut at a thickness of 5 mm and immunostained by a standard ABC method with 3,3 0 diaminobenzidine (DAB) detection and the following primary mouse monoclonal antibodies: 4G8 for Ab (Signet, Dedham, MA, USA) at 1/1000 dilution; AT8 for tau (Innogenetics, Gent, Belgium) at 1/200 dilution; and NCL-L-ASYN (NovoCastra Laboratories Ltd., Newcastle upon Tyne, UK) for -syn at 1/40 dilution. Incubation with these primary antibodies was carried out overnight at 5 C, following antigen unmasking with 90% formic acid (for Ab) or by microwave treatment (for -syn).
Statistical analysis
Individual total -syn (mg/ml) and FILA-1 absorbance signal levels are shown by group (control, Alzheimer's disease and DLB), together with boxplots. These boxes show the minimum, maximum and median level for each group, together with the lower and upper quartile. The vertical length of the box represents the interquartile range (IQR), i.e. the difference between the upper and the lower quartile. This IQR is a measure of dispersion of the variable. The difference between the three groups as to -syn levels was tested with ANOVA after a log-transformation of the total concentration of -syn in order to minimize the influence of outliers.
The association between LB levels and FILA-1 OD signals was assessed in two ways: first, we computed the Spearman Correlation for the DLB group only and second, we computed Spearman Correlation for all 46 subjects.
A P-value of 0.05 or less was considered significant in all statistical tests.
Results
a-Syn fibrils are more stable compared with a-syn oligomers
We have previously demonstrated that the FILA-1 antibody binds to both soluble oligomeric and insoluble -syn aggregates but not to the monomeric form of -syn (Lindersson et al., 2004) . Because this study was aimed at analysing human brain derived -syn oligomers using the FILA-1 antibody, we first compared the stability of the FILA-1 epitope on in vitro formed -syn oligomers and fibrils by subjecting them to the denaturants urea and SDS, and determined the resistance of the FILA-1 epitopes using dot blot analysis. The soluble oligomers and amyloid fibrils of -syn were treated with increasing concentrations of urea (6.5, 7 and 8 M) or SDS (0.25, 0.5, 1 and 2%) for 6 h at room temperature. As shown in Fig. 1A , both types of aggregates were detectable on a dot blot using the FILA-1 antibody and their immunoreactivity remained unchanged for 5 days in PBS at 4 C (data not shown).
Subjecting the two types of aggregates to denaturants revealed however, that the filaments were more stable than the oligomers, which showed a major loss of the epitopes for FILA-1 after treatment with as low as 0.25% SDS. In contrast, treatment of the fibrils with 2% SDS did not affect the signal as compared with the control. However, the signal was dramatically decreased after treatment of fibrils with higher urea concentrations (7 and 8 M), producing the same signal intensity observed in oligomers treated with 6.5 M of urea. These results demonstrate that -syn oligomers are quite stable structures under non-denaturing conditions but their lower stability under denaturing conditions warrants consideration when procedures are designed for tissue extraction.
The FILA-1 antibody does not bind to Ab and tau aggregates
The specificity of the FILA-1 antibody for -syn fibrils is a prerequisite for using it to measure -syn species in extracts from human brains suffering from neurodegenerative diseases. To demonstrate the specificity, we pre-absorbed FILA-1 antibody with fibrils assembled from recombinant -syn, tau40 or synthetic Ab(1-42). We spotted -syn fibrils onto a membrane in twofold dilutions and probed the membrane with FILA-1 pre-absorbed with the different aggregates. Figure 1B shows that the non-preabsorbed FILA-1 antibody recognizes -syn fibrils at all indicated concentrations. When pre-absorbing FILA-1 with -syn fibrils, the signal is decreased significantly, demonstrating that FILA-1 binds to -syn fibrils. When pre-absorbing FILA-1 with Ab or tau40 fibrils, the immobilized -syn fibrils are still recognized by FILA-1, demonstrating that FILA-1 does not bind to fibrils assembled from Ab(1-42) or tau40. Thus, the FILA-1 antibody is highly specific for -syn fibrils. To verify equal amounts of -syn fibrils on the dot blot under the four different conditions, we reprobed the membrane with ASY1 (Fig. 1C) . Furthermore, when we immobilized different amounts of fibrils of -syn, tau40 and Ab onto a membrane, and then probed with FILA-1 antibody, 510 ng -syn fibrils was recognized by FILA-1, but not the tau or Ab fibrils, even at a 1000-fold higher amount (data not shown). Total a-syn concentrations in human brain lysates
In an attempt to measure the total -syn concentration in the human brain samples, brain homogenates from seven controls, 15 Alzheimer's disease and 24 DLB patients with total protein concentration for each sample was 3 mg/ml, were analysed by a sandwich ELISA method developed in our laboratory using anti--syn (211) for capture and FL-140 for detection. Using this ELISA, the total -syn protein concentration was measured in an effort to investigate if the levels of total -syn are altered in the brains of Alzheimer's disease and DLB patients compared with normal brains. Concentrations of recombinant human -syn ranging between 0.001 and 4 mg/ml were used for the standard curve ( Fig. 2A) . The results of the ELISA are shown in Fig. 2A , overall there was no difference in total -syn concentration between DLB and Alzheimer's disease patients compared with controls with the exception of three Alzheimer's disease samples and three DLB samples which contained a relatively higher amount of total -syn (Table 1) . However, when brain samples from DLB patients were compared with the controls, the results did not show any statistically significant difference between the groups (P = 0.47) ( Fig. 2A) .
Detection of a-syn oligomers in human brain lysates by a specific ELISA using FILA-1 antibody
To investigate whether soluble oligomers of -syn are present in brain homogenates of control, Alzheimer's disease and DLB patients, a novel ELISA method was developed using FILA-1. The brain lysates were centrifuged at 100 000 g for 3 h, and the supernatants were coated on the plate, followed by blocking. FILA-1, specific for -syn aggregates, was then used for detection. Using ultracentrifugation before testing the samples by ELISA, we ensured that only soluble oligomers of -syn in the brain samples were detected. Figure 2B illustrates the results obtained by this ELISA for the detection of the oligomeric -syn forms in control, Alzheimer's disease and DLB brain samples. As shown in Fig. 2B , most of the samples from DLB patients and only two samples from Alzheimer's disease patients produced a relatively high signal compared with that obtained from the control brain samples and the rest of the Alzheimer's disease brain samples (Table 1) . Log-transformed FILA-1 signals in the DLB group differed significantly (P50.0001) from those in both the control group and the Alzheimer's disease group, while the difference between the last two groups was not significant (P = 0.32). We also carried out the ELISA on the brain lysates without ultracentrifugation and no differences were observed in the signal levels before and after high-speed centrifugation. This means the brain lysates we prepared under these conditions mainly contain soluble oligomers of -syn rather than mature amyloid fibrils, which would be pelleted by the 3000 g centrifugation. To ensure that no aggregation for the native -syn was taking place during the incubation time, we spiked different amounts of fresh or aggregated recombinant -syn into PBS or normal brain lysates, with final concentrations of -syn protein in the samples being 0.1, 0.2, 0.4, 0.8, 1.6 mg/ml. The samples were incubated for 3 h at 37 C and then tested by the ELISA. Only the samples that were spiked with aggregated -syn gave concentration-dependent high FILA-1 signals, whereas the samples spiked with fresh -syn gave similar signals to the control samples which were not spiked with -syn (data not shown). These results confirm that, at least under these conditions, the high signals detected by the FILA-1 ELISA from the DLB brain samples are from soluble native -syn oligomers present in the DLB brains, and not due the aggregation of -syn during incubation of the brain lysates. Furthermore, to confirm that FILA-1 specifically detected -syn oligomers in the human brains, we used in our ELISA FILA-1 antibody that had been pre-adsorbed with aggregated recombinantsyn. After FILA-1 was pre-adsorbed with increasing concentrations of aggregated -syn (0.001, 0.01, 0.1, 1 and 10 mg/ml) it was then used in the ELISA to test two DLB samples which gave the highest signal in the ELISA. We also tested FILA-1 treated with PBS or non-aggregated -syn protein as a control in these experiments. The ELISA results showed a dramatic decrease in the signal following pre-adsorption with aggregated -syn (data not shown). Pre-adsorption of FILA-1 with aggregated -syn at 0.01 mg/ml marked a point where the signal level of DLB samples dropped below 0.2 OD, whereas, treatment with PBS and fresh -syn samples had no effect on the signal (data not shown). We then screened all the brain lysates by the ELISA involving pre-adsorption of FILA-1 with aggregated -syn, or PBS as a control. Interestingly, a dramatic decrease in the signal levels from DLB patients was recorded following pre-adsorption of FILA-1 with aggregated -syn (Fig. 2C) . However, the signals from the control and Alzheimer's disease samples were also decreased suggesting that soluble oligomers of -syn are normally present at low levels in controls and Alzheimer's disease samples (Fig. 2C) . However, pre-adsorptions of FILA-1 with fibrils formed by tau or Aß (1-42) had no effect on the ELISA signals (data not shown). These findings provide clear evidence supporting the contention that elevated soluble oligomers of -syn are involved in the pathogenesis of DLB. Furthermore, these findings establish the FILA-1 as a very sensitive tool for the detection of -syn oligomers in human brain lysates.
Immunohistochemical staining
As shown in Table 1 , immunostaining revealed rare (4/6 cases) or moderate (1/6 cases) numbers of senile plaques (SPs) in the control brains, with no evidence for the presence of either neurofibrillary tangles (NFTs) or LBs. All 15 brains from cases of Alzheimer's disease contained abundant SPs and NFTs with no LBs. The brains from cases of DLB showed variable numbers of LBs, with SPs being detected in 21/24 cases and NFTs in 19/24 cases. This is consistent with previous observations of some degree of concomitant Alzheimer-type histopathology in 75% of cases of DLB (Perry et al., 1990) . There were no associations between LBs score and FILA-1 signals or total -syn concentration for the DLB group. To test for the possibility that the soluble -syn oligomers that we detected in the DLB brains were produced by the breakdown of LBs during brain extraction, we computed a formal correlation between the LB scores and the FILA-1 OD signals using the Spearman (rank) method (Fig. 3) . There appeared to be no association in the DLB group, with a Spearman correlation of 0.18 (95% CI -0.27 to 0.53, P = 0.40), whereas, in the total group of 46 subjects there was a Spearman correlation of 0.79 (95% CI 0.63-0.89, P50.0001). However, there were no correlations, when involving either Ab or tau scores (data not shown).
Discussion
Recent studies by ourselves and others suggest that 'soluble oligomeric' forms of amyloid proteins, including -syn, might be the pathogenic species that lead to neurodegeneration and neuronal cell death, rather than mature amyloid fibrils (Lambert et al., 1998; Bucciantini et al., 2002; Walsh et al., 2002 Walsh et al., , 2005 Klyubin et al., 2005; Paleologou et al., 2005; Amer et al., 2006) . These -syn oligomers cannot be detected easily in post-mortem brain sections, but there has been some recent success in detecting -syn oligomers in extracts from Parkinson's disease and DLB brains using biochemical methods (Sharon et al., 2003; Klucken et al., 2006) .
Here, we have developed a novel technique for detecting the soluble oligomeric forms of -syn in human brain extracts. This method depends on subjecting brain extracts to high speed centrifugation, to remove insoluble -syn aggregates, followed by specific detection of soluble oligomers in the supernatants by employing FILA-1, an antibody that selectively binds to neoepitopes generated on aggregated forms of -syn and thus not to monomers. One can argue that there is a possibility that some mature fibrils may fragment during the extraction process to produce smaller derivatives that could remain in the supernatant and so contribute to the ELISA results. However, the relatively high stability of -syn fibrils (Fig. 1A) , and the high FILA-1 signals detected in one control and two Alzheimer's disease samples with no LBs, makes this seem unlikely. However, we cannot formally rule out the possibility that some LBs fibrils could break Figure 2 Quantification of total -syn concentration and -syn oligomers in brain lysates. (A) Brain lysates (100 ml/well) with total protein concentration 3 mg/ml were analysed by the ELISA for total concentration of -syn. A box plot of -syn concentration (mg/ml) is shown for the three groups. Inset shows the standard curve of the ELISA, serial dilutions of recombinant human -syn (loaded in triplicates of 100 ml/well) ranging between 4 and 0.001 mg/ml, were analysed on the same plate. One of the data points for the Alzheimer's disease group (sample AD15, 1.29 mg/ml total -syn) has been omitted for clarity. (B) The supernate of ultracentrifuged brain lysates with total protein concentration 3 mg/ml were coated (100 ml/well) in triplicate onto a 96-well plate, and then detected with the FILA-1 antibody. A box plot of -syn soluble oligomers signals (absorbance at 450 nm) is shown. (C) The pre-adsorption of FILA-1 with 0.01 mg/ml of aggregated -syn brought the signal for the control, Alzheimer's disease and DLB brain lysates below the 0.2 absorbance baseline. Alzheimer's disease denotes Alzheimer disease and DLB, dementia with Lewy bodies. Boxes show the minimum, maximum and median level for each group, together with the lower and upper quartile. The vertical length of the box represents the IQR, i.e. the difference between the upper and the lower quartile. Symbols outside the range are outliers (defined as being more than 1.5 IQR's from the end of the box). (Table 1) . Moreover, we demonstrate that purified -syn oligomers are stable under non-denaturing conditions, which is what we employ in our brain extraction.
We then used this novel ELISA method to quantify the amounts of -syn oligomers in extracts prepared from frozen post-mortem brains of control, Alzheimer's disease and DLB patients. The data clearly show a 1.5-fold increase (P50.0001) in the levels of soluble oligomers of -syn in the DLB brain extracts compared with the controls (Fig. 1B) . Overall, the detectable levels of soluble -syn oligomers were low in brain extracts prepared from the Alzheimer's disease and control cases, consistent with the complete absence of LBs in these cases. Detection of elevated amounts of soluble -syn oligomers in the DLB brain extracts was confirmed by experiments involving pre-adsorption of FILA-1 with pre-aggregated -syn protein, which blocked the signals obtain in the ELISA, in contrast to monomeric -syn, which had little effect on the signals. The increased levels of -syn oligomers detected in the DLB brain extracts did not seem to be simply a reflection of increased overall expression of -syn, since the levels of totalsyn were not increased in DLB compared with the controls (Fig. 1A) . This suggests that, in DLB at least, -syn oligomerization is not simply due to an increase in -syn protein expression, but must be due to other factors that promote oligomerization. However, three cases of Alzheimer's disease with higher levels of expression of total -syn also showed slightly higher levels of -syn oligomers. These higher levels in some Alzheimer's disease patients might reflect a potential/precursor to form LBs if the individuals concerned had lived longer. LBs have been found in cases of familial Alzheimer's disease (Lippa et al., 1998) , and incidental LBs are common in many old people. Our demonstration of a low but finite amount of -syn oligomers in the control brain extracts parallels the situation in Alzheimer's disease, where the pathogenic Ab42 peptide is produced at low levels during normal APP metabolism but is increased by disease-causing mutations in its precursor as well as in the presenilin containing -secretase complex (Selkoe, 2004) .
Our data add further support to the idea that soluble oligomeric forms of -syn play an important role in the pathogenesis of the synucleinopathies, although admittedly this could be a result rather than a cause of the disease. The methods developed in this article also provide a reliable and sensitive technique for the assay ofsyn oligomers in tissue extracts and body fluids that will be useful in many future studies.
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